A shift toward a model of AAT deficiency based on functionality—rather than quantity—is warranted; however, quantitative AAT serum assays are widely used and inexpensive, while assays assessing AAT functional activity [15] are utilized in only a handful of specialized laboratories globally. The gene discussed is SERPINA1; the disease is alpha 1-antitrypsin deficiency.